 |
|
|
|
 |
|
|
| Article 1 to 9 out of 9 concerning atugen AG
|
-
SR Pharma plc announces IND for a 2nd siRNA therapeutic based on its unique proprietary chemistry
(20 Mar 2007)
SR Pharma plc announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug application (IND) for a second siRNA therapeutic which is based on the company 's unique proprietary chemistry. The product is AKIi-5, ...
-
SR Pharma plc Announces Start of Phase I trial with Novel RNAi Therapeutic RTP-801i in Age- related Macular Degeneration (AMD)
(07 Feb 2007)
SR Pharma plc announced that Quark Biotech Inc. has started a Phase I clinical trial with RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma plc. RTP-801i is based on Atugen's proprietary ...
-
SR Pharma Granted Core RNAi Patent by the European Patent Office
(08 Jan 2007)
SR Pharma plc announced that the European Patent Office has granted the Company its core RNAi patent EP 03784183.0. This patent covers its novel, stabilised, small interfering RNA (siRNA) molecules with blunt ends and positional modifications. These ...
-
SR Pharma plc Announces Encouraging Results for Atu027 RNAi Showing Therapeutic Efficacy in Mouse Models of Pancreatic Cancer
(15 Sep 2006)
SR Pharma plc and its operating subsidiary Atugen AG announce that studies at the Charité Hospital, Berlin have demonstrated the therapeutic efficacy of Atu027 RNAi in animal models of pancreatic cancer. The data showed both inhibition of cancer ...
-
ALTANA Pharma and Atugen Renew Target Validation and License Agreement
(21 Feb 2005)
Atugen AG announced that it has renewed its non-exclusive Target Validation and License Agreement with ALTANA Pharma AG for another year. The agreement gives Altana the right to have molecular targets validated by Atugen's discovery team, utilizing ...
-
atugen and Aventis to collaborate in identifying siRNA compounds with the potential for therapeutic development
(16 Sep 2004)
Berlin. atugen AG announced that it has signed a collaboration agreement with Aventis to identify siRNA compounds with the potential for therapeutic development. It is planned to combine atugen's proprietary siRNA (short-interfering RNA) technology ...
-
Peter Buckel Appointed CEO of atugen AG
(09 Jun 2004)
Berlin. atugen AG has announced the appointment of Prof Peter Buckel as CEO. This closely follows the strengthening of the board with the appointment of Prof Bernd Wetzel of Boehringer Ingelheim as non-executive director.Peter Buckel brings to ...
-
atugen and Sankyo Sign Multi-Year Contract Research Agreement
(20 May 2004)
Berlin, Germany. atugen AG announced that it has signed a multi-year contract research agreement with Sankyo Co. Ltd, one of Japan's leading pharmaceutical companies. Both companies have already successfully collaborated on a number of proprietary ...
-
atugen AG raises EUR 5 million venture funding for siRNA therapeutics program
(16 Mar 2004)
siRNA therapeutics patent application published
Berlin. atugen AG, The Gene Silencing Company(TM), announced that it has raised EUR5 million in its third financing round since it was founded in 1998. The new investment will enable atugen to accelerate its work on the development of siRNA ...
|
|
|
|
|
Top
